XML 43 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Disaggregated Revenues
 9 Months Ended
Sep. 30, 2019
Disaggregation of Revenue [Abstract]  
Disaggregated Revenues Disaggregated Revenues
The following table summarizes the disaggregation of revenues by nature, in thousands of dollars:
 
Three Months ended September 30,
 
Nine Months ended
September 30,
 
2019
 
2018
 
2019
 
2018
 
(unaudited)
 
(unaudited)
Net product sales
 
 
 
 
 
 
 
Trokendi XR
$
77,332

 
$
79,834

 
$
219,989

 
$
226,863

Oxtellar XR
22,702

 
20,393

 
65,502

 
59,514

Total net product sales
$
100,034

 
$
100,227

 
$
285,491

 
$
286,377

Royalty revenues
2,106

 
2,769

 
6,818

 
5,836

Licensing revenues
—

 
—

 
—

 
750

Total revenues
$
102,140

 
$
102,996

 
$
292,309

 
$
292,963


The majority of the Company’s product sales are to pharmaceutical wholesalers/distributors who, in turn, sell the Company's products to chain and independent pharmacies, hospitals and their other customers. Three pharmaceutical wholesalers/distributors collectively accounted for more than 90% of both the Company’s total net product sales as well as its accounts receivables as of the three and nine months ended September 30, 2019 and 2018, respectively.
The Company recognized noncash royalty revenue of $1.6 million and $5.0 million for the three and nine months ended September 30, 2019, respectively, as compared to the $1.5 million and $4.3 million for the three and nine months ended September 30, 2018, respectively.
For the three and nine months ended September 30, 2019, revenues recognized from performance obligations related to prior periods (e.g., due to changes in transaction price) were not material, in the aggregate, to either Net product sales or to Royalty revenues.